Found: 95
Select item for more details and to access through your institution.
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
Association of Hepatic Steatosis and Fibrosis Indices With Insulin Sensitivity and Inflammation in the POP-ABC Study.
- Published in:
- Journal of the Endocrine Society, 2024, v. 8, n. 4, p. 1, doi. 10.1210/jendso/bvae020
- By:
- Publication type:
- Article
Implementing genetic testing in diabetes: Knowledge, perceptions of healthcare professionals, and barriers in a developing country.
- Published in:
- Population Medicine, 2024, v. 6, p. 1, doi. 10.18332/popmed/184210
- By:
- Publication type:
- Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
- By:
- Publication type:
- Article
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2042, doi. 10.1210/clinem/dgac764
- By:
- Publication type:
- Article
Racial and ethnic disparities in the enrolment of medicare medication therapy management programs.
- Published in:
- Journal of Pharmaceutical Health Services Research, 2023, v. 14, n. 2, p. 188, doi. 10.1093/jphsr/rmad010
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
- By:
- Publication type:
- Article
Cardiometabolic Risk Factors and Incident Cardiovascular Disease Events in Women vs Men With Type 1 Diabetes.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 9, p. e2230710, doi. 10.1001/jamanetworkopen.2022.30710
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
- Published in:
- American Journal of Nephrology, 2022, v. 53, n. 7, p. 516, doi. 10.1159/000524889
- By:
- Publication type:
- Article
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691
- By:
- Publication type:
- Article
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677
- By:
- Publication type:
- Article
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication Adherence...[including commentary by Byron C. Scott].
- Published in:
- American Health & Drug Benefits, 2021, v. 14, n. 3, p. 101
- By:
- Publication type:
- Article
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials.
- Published in:
- Clinical Cardiology, 2021, v. 44, n. 8, p. 1139, doi. 10.1002/clc.23665
- By:
- Publication type:
- Article
Serum urate and cardiovascular events in the DCCT/EDIC study.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-90785-4
- By:
- Publication type:
- Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
- By:
- Publication type:
- Article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
- By:
- Publication type:
- Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
- By:
- Publication type:
- Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
- By:
- Publication type:
- Article
791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-791-P
- By:
- Publication type:
- Article
Genetic Risk Factors for CVD in Type 1 Diabetes: The DCCT/EDIC Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: A pooled analysis of phase III studies.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2276, doi. 10.1111/dom.14150
- By:
- Publication type:
- Article
197-LB: microRNA Expression Profiles and Progression from Normoglycemia to Prediabetes in a Biracial Cohort.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-197-LB
- By:
- Publication type:
- Article
Regression from prediabetes to normal glucose regulation: State of the science.
- Published in:
- Experimental Biology & Medicine, 2020, v. 245, n. 10, p. 889, doi. 10.1177/1535370220915644
- By:
- Publication type:
- Article
Calorie Restriction and Intermittent Fasting: Impact on Glycemic Control in People With Diabetes.
- Published in:
- Diabetes Spectrum, 2020, v. 33, n. 2, p. 143, doi. 10.2337/ds19-0064
- By:
- Publication type:
- Article
Metabolite Profiles of Incident Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Sickle Cell Trait, European Ancestry, and Longitudinal Tracking of HbA<sub>1c</sub> Among African Americans: The Jackson Heart Study.
- Published in:
- 2019
- By:
- Publication type:
- letter
Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS).
- Published in:
- 2019
- By:
- Publication type:
- journal article
A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program.
- Published in:
- Journal of the Endocrine Society, 2019, v. 3, n. 9, p. 1663, doi. 10.1210/js.2019-00069
- By:
- Publication type:
- Article
Response to Comment on Braffett et al. Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664.
- Published in:
- 2019
- By:
- Publication type:
- letter
2426-PUB: Circulating WBC, RBC, and Hemoglobin Level in Relation to Metabolic Syndrome and Incident Prediabetes in a Biracial Cohort of Normoglycemic Subjects with Parental Type 2 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-2426-PUB
- By:
- Publication type:
- Article
1560-P: A History of CHF Predicts Adverse Outcomes of Hospitalizations for Hyperglycemic Crises—Data from National and Local Cohorts.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1560-P
- By:
- Publication type:
- Article
1507-P: Baseline Metabolite Profiles of Incident Type 2 Diabetes and Heterogeneity of Treatment Effect in the Diabetes Prevention Program (DPP).
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1507-P
- By:
- Publication type:
- Article
1719-P: Plasma Glucose Response to Oral Dexamethasone Predicts Incident Prediabetes in Normoglycemic Offspring of Parents with Type 2 Diabetes.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1719-P
- By:
- Publication type:
- Article
1210-P: Pooled Analysis of the Safety and Efficacy of Ertugliflozin in the Elderly.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1210-P
- By:
- Publication type:
- Article
130-OR: Does the Duration of Prediabetes Status Affect Reversibility with Lifestyle Intervention?
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-130-OR
- By:
- Publication type:
- Article
Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Comparative Effectiveness of Medication Therapy Management Eligibility Criteria Across Racial/Ethnic Groups.
- Published in:
- Journal of the American Geriatrics Society, 2019, v. 67, n. 3, p. 581, doi. 10.1111/jgs.15754
- By:
- Publication type:
- Article
Predictive value positive of MTM eligibility criteria under MMA and ACA in identifying individuals with medication utilization issues.
- Published in:
- Journal of Pharmaceutical Health Services Research, 2018, v. 9, n. 4, p. 393, doi. 10.1111/jphs.12266
- By:
- Publication type:
- Article
Genetic Ancestry Markers and Difference in A1c Between African American and White in the Diabetes Prevention Program.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 530, doi. 10.1111/dom.13116
- By:
- Publication type:
- Article
Effect of once‐weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 2, p. 409, doi. 10.1111/dom.13086
- By:
- Publication type:
- Article
Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
- Published in:
- 2017
- By:
- Publication type:
- letter
Plasma lipid levels predict dysglycemia in a biracial cohort of nondiabetic subjects: Potential mechanisms.
- Published in:
- Experimental Biology & Medicine, 2016, v. 241, n. 17, p. 1961, doi. 10.1177/1535370216659946
- By:
- Publication type:
- Article
Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications.
- Published in:
- Experimental Biology & Medicine, 2016, v. 241, n. 12, p. 1323, doi. 10.1177/1535370216654227
- By:
- Publication type:
- Article